Beijing Kleb

Beijing Kleb is a biotechnology company based in China that focuses on the development of bacteriophage therapies to address the growing threat of antimicrobial resistance. The company specializes in the isolation, characterization, and optimization of phages targeting high-priority ESKAPE pathogens, with a particular emphasis on carbapenem-resistant Klebsiella pneumoniae. Beijing Kleb utilizes a proprietary technology platform to create both personalized phage cocktails and standardized therapeutic products for clinical use. Their pipeline includes candidates for respiratory, urinary tract, and systemic infections caused by multi-drug resistant bacteria. The company collaborates with clinical institutions to advance phage therapy through investigator-initiated trials and formal regulatory pathways.